One recent advance and fundamental shift in medicine has been the advent of personalized medicine. Improvements in DNA microarray technology have generated data on a scale that, for the first time, permits detailed scrutiny of the human genome, thereby providing the infrastructure to understand the genetic basis of diseases. These advances have the potential to enhance healthcare management by improving disease diagnosis and implementing treatments adapted to each patient. The traditional approach of “one drug fits all” is no longer acceptable. The advent of custom optimization of drugs and dosages results in better treatment efficacy and enhanced safety [1,2]. The emergence of pharmacogenomics has provided a basis with which to evaluate individual variations in response to treatments. Pharmacogenetic testing aims at determining the underlying genotypic and phenotypic differences in the pharmacodynamics and pharmacokinetics of drug metabolism and, as a result, will become an integral part of the therapeutic monitoring and health management of patients.
|Title of host publication||Biochips as Pathways to Drug Discovery|
|Number of pages||12|
|Publication status||Published - 01 Jan 2006|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)